BioNTech SE (BNTX)
5 Predictions for the Stock Market in 2025 -- and Which Stocks Will Soar the Most If They're Right
Nearly one year ago, I made four predictions about the stock market in 2024. I thought the S&P 500 would generate positive returns but lower than in 2023.
BioNTech enters settlement with US agency, UPenn over COVID vaccine royalties
BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University of Pennyslvania over the payment of royalties related to its COVID-19 vaccine, the company said in filings on Friday.
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
Investing in biotech stocks usually isn't for the faint of heart. These stocks tend to be highly volatile because of the inherent risks of developing new drugs.
US FDA lifts partial clinical hold on BioNTech cancer drug study
BioNTech SE said on Friday it has been informed by its partner OncoC4 that the U.S. Food and Drug Administration has lifted the partial clinical hold on its late-stage trial studying its drug for a type of lung cancer.
2 Healthcare Stocks to Buy Hand Over Fist and 1 to Avoid
I've long viewed healthcare as one of the best sectors for long-term investors because everybody requires healthcare products and services sooner or later. With aging populations in the U.S. and other major countries, the demand will almost certainly increase over the next decade and beyond.
2 No-Brainer Stocks to Buy Before the End of 2024
I think the stock market's valuation has become frothy. And I'm in good company; Warren Buffett's actions show that he shares this opinion.
Why Is BioNTech Stock Trading Higher On Friday?
On Thursday, Duality Biologics revealed the first data from a global Phase 1/2a trial of BNT324/DB-1311, which it co-developed with BioNTech SE BNTX.
5 Top Stocks to Buy in December
The end of the year can spur myriad feelings when deciding which stocks are the best buys.
BioNTech Stock Has Been Hit Hard Since RFK Jr.'s Nomination. Why This Analyst Upgraded It.
Evercore ISI analyst Cory Kasimov upgrades the German drugmaker's stock to Outperform from In Line.
Analysts Turn Bullish on BioNTech Stock Amid Volatility
BioNTech SE ADR (NASDAQ:BNTX) stock is up 2.8% to trade at $825.41 at last glance, after an Evercore ISI upgrade to "outperform" from "in-line.
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up
BioNTech inks a deal to acquire Biotheus and gain full global rights to a bispecific antibody, BNT327/PM8002, being studied for various oncology indications.
BioNTech buys China's Biotheus to support oncology strategy
German drugmaker BioNTech has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain full global rights to the bispecific antibody candidate BNT327, it said on Wednesday.
